Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.
INTRODUCTION
Health-related quality of life (HRQOL) is increasingly recognised as an important end-point in cancer clinical trials. The concept of minimally important difference (MID) enables interpreting differences and changes in HRQOL scores in terms of clinical meaningfulness. We aimed to estimate MIDs for interpreting group-level change of European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) scores in patients with malignant melanoma.


METHODS
Data were pooled from three published melanoma phase III trials. Anchors relying on clinician's ratings, e.g. performance status, were selected using correlation strength and clinical plausibility of associating the anchor/EORTC QLQ-C30 scale pair. HRQOL change was evaluated between time periods that were common to all trials: start of treatment to end of treatment and end of treatment to end of follow-up. Three change status groups were formed: deteriorated by one anchor category, improved by one anchor category and no change. Patients with greater anchor change were excluded. The mean change method and linear regression were used to estimate MIDs for change in HRQOL scores within the group and between the groups of patients, respectively.


RESULTS
MIDs varied according to QLQ-C30 scale, direction (improvement versus deterioration), anchor and period. MIDs for within-group change ranged from 4 to 18 points (improvement) and -16 to -4 points (deterioration), and MIDs for between-group change ranged from 3 to 16 points and from -16 to -3 points. MIDs for most of QLQ-C30 scales ranged from 5 to 10 points in absolute values.


CONCLUSIONS
These results are useful for interpreting changes in EORTC QLQ-C30 scores over time and for performing more accurate sample size calculations in adjuvant melanoma settings.
['Musoro|Jammbe Z|JZ|', 'Bottomley|Andrew|A|', 'Coens|Corneel|C|', 'Eggermont|Alexander Mm|AM|', 'King|Madeleine T|MT|', 'Cocks|Kim|K|', 'Sprangers|Mirjam Ag|MA|', 'Groenvold|Mogens|M|', 'Velikova|Galina|G|', 'Flechtner|Hans-Henning|HH|', 'Brandberg|Yvonne|Y|', '|||']
D000368:Aged D000074322:Antineoplastic Agents, Immunological D000073116:Cancer Survivors D017024:Chemotherapy, Adjuvant D017326:Clinical Trials, Phase III as Topic D003131:Combined Modality Therapy D005260:Female D006801:Humans D007167:Immunotherapy D000077190:Interferon alpha-2 D016898:Interferon-alpha D000074324:Ipilimumab D016014:Linear Models D008297:Male D008545:Melanoma D008875:Middle Aged D011092:Polyethylene Glycols D011788:Quality of Life D016032:Randomized Controlled Trials as Topic D011994:Recombinant Proteins D011795:Surveys and Questionnaires
Malignant melanoma Health-related quality of life Minimally important difference EORTC QLQ-C30